160 related articles for article (PubMed ID: 38582683)
21. Two decades of commitment to malaria vaccine development: GlaxoSmithKline Biologicals.
Ballou WR; Cahill CP
Am J Trop Med Hyg; 2007 Dec; 77(6 Suppl):289-95. PubMed ID: 18165505
[TBL] [Abstract][Full Text] [Related]
22. Increase of Dose Associated With Decrease in Protection Against Controlled Human Malaria Infection by PfSPZ Vaccine in Tanzanian Adults.
Jongo SA; Church LWP; Mtoro AT; Schindler T; Chakravarty S; Ruben AJ; Swanson PA; Kassim KR; Mpina M; Tumbo AM; Milando FA; Qassim M; Juma OA; Bakari BM; Simon B; James ER; Abebe Y; Kc N; Saverino E; Fink M; Cosi G; Gondwe L; Studer F; Styers D; Seder RA; Schindler T; Billingsley PF; Daubenberger C; Sim BKL; Tanner M; Richie TL; Abdulla S; Hoffman SL
Clin Infect Dis; 2020 Dec; 71(11):2849-2857. PubMed ID: 31782768
[TBL] [Abstract][Full Text] [Related]
23. Attenuated PfSPZ Vaccine induces strain-transcending T cells and durable protection against heterologous controlled human malaria infection.
Lyke KE; Ishizuka AS; Berry AA; Chakravarty S; DeZure A; Enama ME; James ER; Billingsley PF; Gunasekera A; Manoj A; Li M; Ruben AJ; Li T; Eappen AG; Stafford RE; Kc N; Murshedkar T; Mendoza FH; Gordon IJ; Zephir KL; Holman LA; Plummer SH; Hendel CS; Novik L; Costner PJ; Saunders JG; Berkowitz NM; Flynn BJ; Nason MC; Garver LS; Laurens MB; Plowe CV; Richie TL; Graham BS; Roederer M; Sim BK; Ledgerwood JE; Hoffman SL; Seder RA
Proc Natl Acad Sci U S A; 2017 Mar; 114(10):2711-2716. PubMed ID: 28223498
[TBL] [Abstract][Full Text] [Related]
24. A Malaria Vaccine for Africa - An Important Step in a Century-Long Quest.
Alonso PL; O'Brien KL
N Engl J Med; 2022 Mar; 386(11):1005-1007. PubMed ID: 35275477
[No Abstract] [Full Text] [Related]
25. Rolling back malaria in Africa - challenges and opportunities to winning the elimination battle.
Maharaj R; Kissoon S; Lakan V; Kheswa N
S Afr Med J; 2019 Dec; 109(11b):53-56. PubMed ID: 32252869
[TBL] [Abstract][Full Text] [Related]
26. WITHDRAWN: Vaccines for preventing malaria.
Graves P; Gelband H
Cochrane Database Syst Rev; 2007 Jul; 2003(4):CD000129. PubMed ID: 17636596
[TBL] [Abstract][Full Text] [Related]
27. Vaccines for preventing malaria.
Graves P; Gelband H
Cochrane Database Syst Rev; 2003; (1):CD000129. PubMed ID: 12535387
[TBL] [Abstract][Full Text] [Related]
28. Methods for determining vaccine efficacy and effectiveness and the main barriers to developing a fully deployable malaria vaccine.
Guinovart C; Alonso PL
Am J Trop Med Hyg; 2007 Dec; 77(6 Suppl):276-81. PubMed ID: 18165503
[TBL] [Abstract][Full Text] [Related]
29. Malaria vaccine: a step toward elimination.
Jindal H; Bhatt B; Malik JS; Sk S; Mehta B
Hum Vaccin Immunother; 2014; 10(6):1752-4. PubMed ID: 24643280
[TBL] [Abstract][Full Text] [Related]
30. The impact of Loa loa microfilaraemia on research subject retention during a whole sporozoite malaria vaccine trial in Equatorial Guinea.
Manock SR; Nsue VU; Olotu A; Mpina M; Nyakarungu E; Raso J; Mtoro A; Ondo Mangue ME; Ntutumu Pasialo BE; Nguema R; Riyahi P; Schindler T; Daubenberger C; Church LWP; Billingsley PF; Richie TL; Abdulla S; Hoffman SL
Trans R Soc Trop Med Hyg; 2022 Aug; 116(8):745-749. PubMed ID: 35394038
[TBL] [Abstract][Full Text] [Related]
31. European Malaria Vaccine Initiative: portfolio and perspectives for the future.
Imoukhuede EB; Ventura R; Imbault N; van Schooten H; Leroy O
Hum Vaccin; 2010 Jan; 6(1):146-50. PubMed ID: 20009515
[TBL] [Abstract][Full Text] [Related]
32. [Achievements and perspectives of research into development of a vaccine against malaria].
Wiśniewski M; Zak DJ
Wiad Parazytol; 2010; 56(2):133-40. PubMed ID: 20707297
[TBL] [Abstract][Full Text] [Related]
33. Design of a phase III multicenter trial to evaluate the efficacy of the RTS,S/AS01 malaria vaccine in children across diverse transmission settings in Africa.
Leach A; Vekemans J; Lievens M; Ofori-Anyinam O; Cahill C; Owusu-Agyei S; Abdulla S; Macete E; Njuguna P; Savarese B; Loucq C; Ballou WR;
Malar J; 2011 Aug; 10():224. PubMed ID: 21816029
[TBL] [Abstract][Full Text] [Related]
34. Increased levels of anti-PfCSP antibodies in post-pubertal females versus males immunized with PfSPZ Vaccine does not translate into increased protective efficacy.
Kc N; Church LWP; Riyahi P; Chakravarty S; Seder RA; Epstein JE; Lyke KE; Mordmüller B; Kremsner PG; Sissoko MS; Healy S; Duffy PE; Jongo SA; Nchama VUNN; Abdulla S; Mpina M; Sirima SB; Laurens MB; Steinhardt LC; Oneko M; Li M; Murshedkar T; Billingsley PF; Sim BKL; Richie TL; Hoffman SL
Front Immunol; 2022; 13():1006716. PubMed ID: 36389797
[TBL] [Abstract][Full Text] [Related]
35. Sterile protection against human malaria by chemoattenuated PfSPZ vaccine.
Mordmüller B; Surat G; Lagler H; Chakravarty S; Ishizuka AS; Lalremruata A; Gmeiner M; Campo JJ; Esen M; Ruben AJ; Held J; Calle CL; Mengue JB; Gebru T; Ibáñez J; Sulyok M; James ER; Billingsley PF; Natasha KC; Manoj A; Murshedkar T; Gunasekera A; Eappen AG; Li T; Stafford RE; Li M; Felgner PL; Seder RA; Richie TL; Sim BK; Hoffman SL; Kremsner PG
Nature; 2017 Feb; 542(7642):445-449. PubMed ID: 28199305
[TBL] [Abstract][Full Text] [Related]
36. Clinical development of malaria vaccines: should earlier trials be done in malaria endemic countries?
Chilengi R
Hum Vaccin; 2009 Sep; 5(9):627-36. PubMed ID: 19617708
[TBL] [Abstract][Full Text] [Related]
37. The role of different components of the immune system against Plasmodium falciparum malaria: Possible contribution towards malaria vaccine development.
Mandala WL; Harawa V; Dzinjalamala F; Tembo D
Mol Biochem Parasitol; 2021 Nov; 246():111425. PubMed ID: 34666102
[TBL] [Abstract][Full Text] [Related]
38. Experience and challenges from clinical trials with malaria vaccines in Africa.
Mwangoka G; Ogutu B; Msambichaka B; Mzee T; Salim N; Kafuruki S; Mpina M; Shekalaghe S; Tanner M; Abdulla S
Malar J; 2013 Mar; 12():86. PubMed ID: 23496910
[TBL] [Abstract][Full Text] [Related]
39. Safety, Immunogenicity, and Protective Efficacy against Controlled Human Malaria Infection of
Jongo SA; Shekalaghe SA; Church LWP; Ruben AJ; Schindler T; Zenklusen I; Rutishauser T; Rothen J; Tumbo A; Mkindi C; Mpina M; Mtoro AT; Ishizuka AS; Kassim KR; Milando FA; Qassim M; Juma OA; Mwakasungula S; Simon B; James ER; Abebe Y; Kc N; Chakravarty S; Saverino E; Bakari BM; Billingsley PF; Seder RA; Daubenberger C; Sim BKL; Richie TL; Tanner M; Abdulla S; Hoffman SL
Am J Trop Med Hyg; 2018 Aug; 99(2):338-349. PubMed ID: 29943719
[TBL] [Abstract][Full Text] [Related]
40. Development of a metabolically active, non-replicating sporozoite vaccine to prevent Plasmodium falciparum malaria.
Hoffman SL; Billingsley PF; James E; Richman A; Loyevsky M; Li T; Chakravarty S; Gunasekera A; Chattopadhyay R; Li M; Stafford R; Ahumada A; Epstein JE; Sedegah M; Reyes S; Richie TL; Lyke KE; Edelman R; Laurens MB; Plowe CV; Sim BK
Hum Vaccin; 2010 Jan; 6(1):97-106. PubMed ID: 19946222
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
